A Double-Blinded, Placebo-Controlled, Single-Dose and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof of Concept of DM199 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Rinvecalinase alfa (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
- Sponsors DiaMedica
- 18 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jul 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 15 Jan 2014 Planned End Date changed from 1 Feb 2014 to 1 Sep 2014 as reported in ClinicalTrial.gov record.